Premium
Production and characterization of monoclonal antibodies against human neuroblastoma
Author(s) -
Schönmann S. M.,
Iyer J.,
Laeng H.,
Gerber H. A.,
Käser H.,
Blaser K.
Publication year - 1986
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910370214
Subject(s) - neuroblastoma , ganglioneuroblastoma , ganglioneuroma , adrenal medulla , monoclonal antibody , cell culture , biology , pheochromocytoma , antigen , microbiology and biotechnology , pathology , antibody , cancer research , endocrinology , immunology , medicine , catecholamine , genetics
MAb were derived from mice immunized with cells of the human neuroblastoma line IMR‐32. Five hybridomas were selected according to their selective binding to human cell lines, tumors and normal tissues. One of them, CE7, reacted with all sympatho‐adreno‐medullary cells (neuroblastoma, ganglioneuroblastoma, ganglioneuroma, pheochromocytoma, adrenal medulla, sympathetic ganglion cells). Weak cross‐reactivities were observed with melanocytes and with some human melanoma and glioma cell lines. The antigen recognized by CE7 was markedly expressed on neuroblastoma tumors of all histological grades, independently of the adrenergic or cholinergic nature of these cells. MAb derived from clones AD2, BCI, BC4 and CB10 bound variably to some, but not to all, neuroblastoma cells. By using these MAb, 3 phenotypes of neuroblastoma lines could be distinguished. The binding profiles of these types, however, showed no correlation with origin of the cell lines or stage of the disease.